147 / 172
147
38. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J,
Weisman M, et al. Infliximab (chimeric anti-tumour necrosis
factor alpha monoclonal antibody) versus placebo in
rheumatoid
arthritis
patients
receiving
concomitant
methotrexate: a randomised phase III trial. ATTRACT Study
Group. Lancet 1999;354:1932-9.
39. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E,
Maxwell L, Macdonald JK,et al.Adverse effects of biologics: a
network meta-analysis and Cochrane overview. Cochrane
Database Syst Rev 2011;(2):CD008794.
40. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a
Cochrane systematic review. J Rheumatol 2010;37:234-45.
41. Westhovens R, Robles M, Ximenes AC, Nayiager S,
Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of
abatacept in methotrexate-naive patients with early
rheumatoid arthritis and poor prognostic factors. Ann Rheum
Dis 2009;68:1870-7.
42. Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt
J, Durez P, et al. Sustained disease remission and inhibition of
radiographic progression in methotrexate-naïve patients with
rheumatoid arthritis and poor prognostic factors treated with
abatacept: 2-year outcomes. Ann Rheum Dis 2011;70:1949-56.
43. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A,
et al. Patient-reported outcomes improve with etanercept plus
methotrexate in active early rheumatoid arthritis and the
improvement is strongly associated with remission: the
COMET trial. Ann Rheum Dis 2010;69:222-5.
44. Emery P, Fleischmann RM, Moreland LW, Hsia EC,
Strusberg I, Durez P, et al. Golimumab, a human anti-tumor
necrosis factor alpha monoclonal antibody, injected
subcutaneously every four weeks in methotrexate-naive
patients with active rheumatoid arthritis: twenty-four-week
results of a phase III, multicenter, randomized, double-blind,
placebo-controlled study of golimumab before methotrexate as